Helix BioMedix merges science and care to create innovative dermatologic treatments. We’re transforming skin health with precision, safety and purpose.
Disease Focus
Xeroderma Pigmentosum (XP)
Helix BioMedix is advancing preclinical research for a potential treatment targeting Xeroderma Pigmentosum — a rare genetic disorder that impairs the skin’s ability to repair UV-induced damage.
READ MORE...
Programs
Our drug development program focuses on early-stage research and discovery in dermatological and genetic disorders. We emphasize rigorous science and targeted innovation to bring forward potential therapeutic candidates.
READ MORE...
Investors
Helix BioMedix is a privately held biotechnology company focused on long-term value creation through responsible research and transparent governance. For updates and corporate information, please visit our Investor section.